Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ID: DRG0ZCEIQ)
ADC Name
Ab4-AM1 D265C.LALA.H436A
Synonyms
Ab4-AM1 D265C.LALA.H436A
   Click to Show/Hide
Organization
Vor Biopharma Inec.
Drug Status
Investigative
Antibody Name
Undisclosed
Antigen Name
Receptor-type tyrosine-protein phosphatase C (PTPRC)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
Undisclosed
2027 Update
General Information of The ADMET Data Related to This ADC
Absorption
Click To Hide/Show 3 Absorption Data Related to This Level
Standard Type Value Units Description Reference
Area Under the Concentration-Time Curve (AUC) 96.6 ug/mL/mg
The overlay of the anti-amatoxin detection-based PK with the anti-IgG detection-based PK indicated the ADC was serum stable.
 [1]
Maximum Observed Concentration (Cmax) 16.5 ug/mL/mg
The overlay of the anti-amatoxin detection-based PK with the anti-IgG detection-based PK indicated the ADC was serum stable.
 [1]
Time to Maximum Concentration (Tmax) 0.083 hr
The overlay of the anti-amatoxin detection-based PK with the anti-IgG detection-based PK indicated the ADC was serum stable.
 [1]
Distribution
Click To Hide/Show 1 Distribution Data Related to This Level
Standard Type Value Units Description Reference
Volume of Distribution (Vd) 54.3 mL/kg
The overlay of the anti-amatoxin detection-based PK with the anti-IgG detection-based PK indicated the ADC was serum stable.
 [1]
Excretion
Click To Hide/Show 2 Excretion Data Related to This Level
Standard Type Value Units Description Reference
Elimination Half-Life (t1/2) 3.21 hr
The overlay of the anti-amatoxin detection-based PK with the anti-IgG detection-based PK indicated the ADC was serum stable.
 [1]
Clearance (CL) 10.4 mL/hr/kg
The overlay of the anti-amatoxin detection-based PK with the anti-IgG detection-based PK indicated the ADC was serum stable.
 [1]
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal inhibitory Concentration (IC50) 
0.026
nM
CVCL_1650
B acute lymphoblastic leukemia
Half Maximal inhibitory Concentration (IC50) 
0.28
nM
CVCL_1650
B acute lymphoblastic leukemia
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (IC50) 0.026 nM Positive CD45,Ab4 expression (CD45,Ab4 +++/++)
Method Description
In vitro REH cell line killing assay - IC50 values
In Vitro Model B acute lymphoblastic leukemia Reh cells CVCL_1650
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (IC50) 0.28 nM Positive CD45,Ab4 expression (CD45,Ab4 +++/++)
Method Description
In vitro REH cell line killing assay - IC50 values
In Vitro Model B acute lymphoblastic leukemia Reh cells CVCL_1650
References
Ref 1 Anti-CD45 antibodies and conjugates thereof